Multiple Myeloma | Clinical

Nadeem Considers Transplant and Quadruplet Regimens in Newly Diagnosed Multiple Myeloma

July 20, 2021

In an interview with Targeted Oncology, Omar Nadeem, MD, the clinical director of the Myeloma Cellular Therapies Program at the Harvard Medical School and physician at the Dana-Farber Cancer Institute, discusses transplant and quadruplet regimens in newly diagnosed multiple myeloma.

Unique Immunotherapy Combos Evaluated in Advanced Melanoma

July 20, 2021

Immune-checkpoint inhibitor therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.

FDA Approves Daratumumab Triplet for Previously Treated Multiple Myeloma

July 12, 2021

The FDA has granted approval to the combination of daratumumab and hyaluronidase-fihj and pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.

FDA Requests Partial Clinical Hold on Melflufen Studies Following Mixed OS Results in R/R Myeloma Subgroups

July 08, 2021

The FDA has placed a partial clinical hold on clinical trials evaluating the first-in-class peptide-drug conjugate, melphalan flufenamide pending a full benefit/risk profile on the agent for use as an early line of therapy in patients with relapsed or refractory multiple myeloma.